Shun Shimizu

USPTO Granted Patents = 10 (Patent Applications = 8)

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 2)

Average Co-Inventor Count = 7.3

ph-index = 3

Forward Citations = 35(Granted Patents)

Company Filing History:

10 out of 947

Chugai Seiyaku Kabushiki Kaisha

where one patent can have more than one assignee

Years Active: 2018-2025

where 'Filed Patents' based on already Granted Patents

10 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12448451 - Anti-CTLA-4 antibody and use thereof (2025-10-21),

2. 12415857 - Anti-CTLA-4 antibody and use thereof (2025-09-16),

3. 12304960 - Anti-CD137 antigen-binding molecule and utilization thereof (2025-05-20),

4. 11952422 - Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137 (2024-04-09),

5. 11912989 - Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules (2024-02-27),

6. 11891434 - Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly (2024-02-06),

7. 11673947 - Target tissue-specific antigen-binding molecule (2023-06-13),

8. 11243210 - Ion concentration-dependent binding molecule library (2022-02-08),

9. 10961530 - Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules (2021-03-30),

10. 10024867 - Ion concentration-dependent binding molecule library (2018-07-17),

Title: The Innovative Contributions of Shun Shimizu

Introduction

Shun Shimizu, a talented inventor based in Shizuoka, Japan, has made significant contributions to the field of biomedical research. With a remarkable portfolio encompassing eight patents, Shimizu is at the forefront of developing groundbreaking therapies that target specific antigens for improved patient outcomes.

Latest Patents

Among his latest innovations are two notable patents focusing on anti-CD137 antigen-binding molecules. The first patent outlines a series of anti-CD137 antigen-binding molecules designed to activate immunocytes while minimizing adverse effects on non-tumor tissues. This innovation aims to enhance cytotoxic activity and anti-tumor efficacy. The second patent highlights the development of antigen-binding molecules that possess altered antibody variable regions capable of binding to both CD3 and CD137. This patent also describes methods for efficiently creating antigen-binding domains that target multiple antigens simultaneously.

Career Highlights

Shimizu's career has been marked by his association with Chugai Seiyaku Kabushiki Kaisha, a leading pharmaceutical company. His commitment to innovation has set a benchmark in the industry, paving the way for advanced therapeutic solutions. His expertise in the field of antigen-binding molecules positions him as a vital contributor to the ongoing research aimed at creating effective cancer treatments.

Collaborations

Throughout his career, Shun Shimizu has collaborated with esteemed colleagues such as Tomoyuki Igawa and Naoka Hironiwa. These collaborations have further propelled his advancements in the realm of immunotherapy and have facilitated the sharing of knowledge and innovation within the company and the broader scientific community.

Conclusion

Shun Shimizu's work exemplifies the power of innovation in addressing complex medical challenges. With a strong focus on creating targeted therapies that minimize side effects while maximizing efficacy, he continues to inspire future generations of inventors and researchers in the biomedical field. His contributions not only reflect his ingenuity but also showcase the potential for transformative change within healthcare.

This text is generated by artificial intelligence and may not be accurate.